Clinical Trend of the Week (December 31-January 6): Ocrelizumab
An OPERA is responsible for this week's top search term. Specifically, results from the OPERA 1, OPERA 2, and ORATORIO randomized controlled trials were recently published. They show that the humanized monoclonal antibody ocrelizumab was effective in reducing disease activity and progression in patients with relapsing multiple sclerosis (MS) or primary progressive MS. The findings are being met with excitement and optimism, even if longer-term studies are required to consider side effects and other concerns. The potential for a new treatment in patients with this challenging condition no doubt resulted in this week's top clinical trend.
For more information on Multiple Sclerosis, read here.
Medscape © 2017
WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Ryan Syrek. Clinical Trends for January 2017 - Medscape - Jan 06, 2017.
Comments